Literature DB >> 24995417

Withaferin A modulates the Spindle assembly checkpoint by degradation of Mad2-Cdc20 complex in colorectal cancer cell lines.

Tania Das1, Kumar Singha Roy2, Tulika Chakrabarti3, Sibabrata Mukhopadhyay3, Susanta Roychoudhury4.   

Abstract

Withania somnifera L. Dunal (Ashwagandha) is used over centuries in the ayurvedic medicines in India. Withaferin A, a withanolide, is the major compound present in leaf extract of the plant which shows anticancer activity against leukemia, breast cancer and colorectal cancer. It arrests the ovarian cancer cells in the G2/M phase in dose dependent manner. In the current study we show the effect of Withaferin A on cell cycle regulation of colorectal cancer cell lines HCT116 and SW480 and its effect on cell fate. Treatment of these cells with this compound leads to apoptosis in a dose dependent manner. It causes the G2/M arrest in both the cell lines. We show that Withaferin A (WA) causes mitotic delay by blocking Spindle assembly checkpoint (SAC) function. Apoptosis induced by Withaferin A is associated with proteasomal degradation of Mad2 and Cdc20, an important constituent of the Spindle Checkpoint Complex. Further overexpression of Mad2 partially rescues the deleterious effect of WA by restoring proper anaphase initiation and keeping more number of cells viable. We hypothesize that Withaferin A kills cancer cells by delaying the mitotic exit followed by inducing chromosome instability.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cdc20; Chromosome instability; Mad2; Spindle assembly checkpoint; Withaferin A

Mesh:

Substances:

Year:  2014        PMID: 24995417     DOI: 10.1016/j.bcp.2014.06.022

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  21 in total

Review 1.  Withania somnifera: From prevention to treatment of cancer.

Authors:  Dushani L Palliyaguru; Shivendra V Singh; Thomas W Kensler
Journal:  Mol Nutr Food Res       Date:  2016-01-29       Impact factor: 5.914

Review 2.  Targeting Cdc20 as a novel cancer therapeutic strategy.

Authors:  Lixia Wang; Jinfang Zhang; Lixin Wan; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Pharmacol Ther       Date:  2015-04-04       Impact factor: 12.310

3.  Cell division cycle 20 promotes cell proliferation and invasion and inhibits apoptosis in osteosarcoma cells.

Authors:  Guanning Shang; Xu Ma; Gang Lv
Journal:  Cell Cycle       Date:  2017-12-22       Impact factor: 4.534

4.  Synergistic antileukemic therapies in NOTCH1-induced T-ALL.

Authors:  Marta Sanchez-Martin; Alberto Ambesi-Impiombato; Yue Qin; Daniel Herranz; Mukesh Bansal; Tiziana Girardi; Elisabeth Paietta; Martin S Tallman; Jacob M Rowe; Kim De Keersmaecker; Andrea Califano; Adolfo A Ferrando
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-07       Impact factor: 11.205

Review 5.  Broad-spectrum antitumor properties of Withaferin A: a proteomic perspective.

Authors:  Martin Dom; Wim Vanden Berghe; Xaveer Van Ostade
Journal:  RSC Med Chem       Date:  2019-12-16

6.  CDC20 is a novel biomarker for improved clinical predictions in epithelial ovarian cancer.

Authors:  Xiaoxue Xi; Tianyue Cao; Yonghong Qian; Huiling Wang; Songwen Ju; Youguo Chen; Ting Chen; Jian Yang; Biaoquan Liang; Shunyu Hou
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

7.  Diosgenin exerts its tumor suppressive function via inhibition of Cdc20 in osteosarcoma cells.

Authors:  Cheng Long; Juan Chen; Hua Zhou; Tao Jiang; Xiang Fang; Dong Hou; Ping Liu; Hong Duan
Journal:  Cell Cycle       Date:  2019-01-22       Impact factor: 4.534

Review 8.  Perspectives on natural compounds in chemoprevention and treatment of cancer: an update with new promising compounds.

Authors:  Abedul Haque; Daniel Brazeau; Arm R Amin
Journal:  Eur J Cancer       Date:  2021-04-14       Impact factor: 9.162

9.  CDC20 maintains tumor initiating cells.

Authors:  Qi Xie; Qiulian Wu; Stephen C Mack; Kailin Yang; Leo Kim; Christopher G Hubert; William A Flavahan; Chengwei Chu; Shideng Bao; Jeremy N Rich
Journal:  Oncotarget       Date:  2015-05-30

Review 10.  Withaferin-A--A Natural Anticancer Agent with Pleitropic Mechanisms of Action.

Authors:  In-Chul Lee; Bu Young Choi
Journal:  Int J Mol Sci       Date:  2016-03-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.